Identification of Kd restricted immunogenic peptides in mouse mammary tumor virus gag or env proteins (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Identification of Kd restricted immunogenic peptides in mouse mammary tumor virus gag or env proteins (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 35:A2984 1994. Unique Identifier : AIDSLINE ICDB/95604669
Wei WZ; Gill RF; Abastado JP; Michigan Cancer Foundation, Detroit, MI 48201

Abstract: To identify MMTV immunogenic peptides, 27 peptides with sequences homologous to that of MMTV gag or env proteins and with the reported Kd motif were synthesized. Peptide binding to Kd was determined in a competition binding assay by measuring the decrease in binding of an 125I-labeled control peptide to a soluble single chain Kd-beta 2M (SC-Kd) fusion protein when test peptide is added. Of the 27 peptides, G425, E372, E474, E624 and E626 demonstrate strong binding to SC-Kd and G504; E103 and E645 showed moderate binding. The immunogenicity of G425, G504 and E103 and a nonbinding E478 was tested by iv injection of BALB/c mice with peptide coated splenocytes. A single injection of G425 induced strong CTLs, and three injections of E103 induced weak CTLs. CTL lysed peptide coated normal and tumor cells, but not untreated MMTV infected tumor cells. G504 and E478 did not induce CTL response. The binding assay is, therefore, predictive of the peptide immunogenicity. These results also suggest that G425 and E103 may be cryptic peptides and that mammary tumor cells are susceptible to MHC restricted CTL when appropriate peptides are presented. The immunogenicity of the other SC-Kd binding MMTV peptides is being tested.

Keywords: Animal Gene Products, gag/*METABOLISM Mammary Neoplasms/IMMUNOLOGY/*METABOLISM Mice Peptides/IMMUNOLOGY/*ISOLATION & PURIF T-Lymphocytes, Cytotoxic/IMMUNOLOGY ABSTRACT
950330
M9530834

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .